Wegner Erik, Slotina Ekaterina, Mickan Tim, Truffel Sebastian, Arand Charlotte, Wagner Daniel, Ritz Ulrike, Rommens Pol M, Gercek Erol, Drees Philipp, Baranowski Andreas
Biomatics Group, Department of Orthopaedics and Traumatology, University Medical Centre of the Johannes Gutenberg University, 55131 Mainz, Germany.
Pharmaceutics. 2022 Feb 26;14(3):523. doi: 10.3390/pharmaceutics14030523.
The antifibrotic effect of atorvastatin has already been demonstrated in several organ systems. In the present study, a rat model was used to investigate the effect of atorvastatin on posttraumatic joint contracture. Forty-eight Sprague Dawley rats were equally randomized into an atorvastatin group and a control group. After initial joint trauma, knee joints were immobilized for intervals of 2 weeks (n = 16) or 4 weeks (n = 16) or immobilized for 4 weeks with subsequent remobilization for another 4 weeks (n = 16). Starting from the day of surgery, animals received either atorvastatin or placebo daily. After euthanasia at week 2, 4 or 8, joint contracture was determined, histological examinations were performed, and gene expression was assessed. The results suggest that the joint contracture was primarily arthrogenic. Atorvastatin failed to significantly affect contracture formation and showed a reduction in myofibroblast numbers to 98 ± 58 (control: 319 ± 113, p < 0.01) and a reduction in joint capsule collagen to 60 ± 8% (control: 73 ± 9%, p < 0.05) at week 2. Gene expression of α-smooth muscle actin (α-SMA), collagen type I, transforming growth factor β1 (TGF-β1) and interleukin-6 (IL-6) was not significantly affected by atorvastatin. Atorvastatin decreases myofibroblast number and collagen deposition but does not result in an improvement in joint mobility.
阿托伐他汀的抗纤维化作用已在多个器官系统中得到证实。在本研究中,使用大鼠模型来研究阿托伐他汀对创伤后关节挛缩的影响。48只Sprague Dawley大鼠被随机均分为阿托伐他汀组和对照组。初始关节创伤后,膝关节固定2周(n = 16)或4周(n = 16),或固定4周后再活动4周(n = 16)。从手术当天开始,动物每天接受阿托伐他汀或安慰剂。在第2、4或8周安乐死后,测定关节挛缩情况,进行组织学检查,并评估基因表达。结果表明,关节挛缩主要是关节源性的。阿托伐他汀未能显著影响挛缩形成,在第2周时肌成纤维细胞数量减少至98±58(对照组:319±113,p<0.01),关节囊胶原蛋白减少至60±8%(对照组:73±9%,p<0.05)。阿托伐他汀对α-平滑肌肌动蛋白(α-SMA)、I型胶原蛋白、转化生长因子β1(TGF-β1)和白细胞介素-6(IL-6)的基因表达没有显著影响。阿托伐他汀可减少肌成纤维细胞数量和胶原蛋白沉积,但并未改善关节活动度。